HS
ARQT icon

HighVista Strategies’s Arcutis Biotherapeutics ARQT Stock Holding History

HighVista Strategies’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-34,462
Closed -$734K – 114
2022
Q2 		$734K Buy
+34,462
New +$707K 0.44% 52

Other funds holding ARQT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

HighVista Strategies's ARQT Position: Q3 2022 in Review

HighVista Strategies sold out of Arcutis Biotherapeutics (ARQT) in Q3 2022, closing a stake of 34,462 shares — an estimated $734K sold.

HighVista Strategies first reported a position in ARQT in Q2 2022 and held it in 1 quarter. The position peaked at $734K in Q2 2022. 139 funds tracked by Wall St. Rank hold ARQT as of Q3 2022.

  • HighVista Strategies reported no remaining Arcutis Biotherapeutics position as of Q3 2022 after selling out during the quarter.
  • HighVista Strategies sold 34,462 Arcutis Biotherapeutics shares in Q3 2022, an estimated $734K.
  • HighVista Strategies first reported a position in Arcutis Biotherapeutics in Q2 2022 and held it in 1 quarter.
  • HighVista Strategies's Arcutis Biotherapeutics position peaked at $734K in Q2 2022.
  • 139 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2022.

Based on HighVista Strategies's 13F filing for Q3 2022, filed 14 Nov 2022.